Mission BioCapital

What Mission BioCapital does

Mission BioCapital is a Cambridge, Massachusetts-headquartered life science venture capital firm founded in 2009 that invests in early-stage biotech, medtech, diagnostics, lab tools, and drug delivery companies. The firm is disease- and modality-agnostic but prioritizes novel therapeutics, and currently invests out of Fund VI (closed at $143.75 million in November 2025) following Fund V ($275 million, November 2021). Mission BioCapital co-creates companies alongside academic researchers — including ARase Therapeutics, Arclight Therapeutics, Jupiter Bioventures, and Telo Therapeutics — and operates a differentiated "launchpad" model combining capital with physical infrastructure and partner services. The Platinum Program, launched in 2022 as the firm's flagship annual accelerator, awards up to $500,000 in pre-seed SAFE capital to roughly eight winners per year, alongside a guaranteed lab bench in 22 affiliated incubator cities, drug discovery services from Alloy Therapeutics, HitGen, and CCRM, and legal/accounting services from Goodwin Procter, Norton Rose Fulbright, and van den Boom & Associates.

The firm generates revenue through two primary streams: (1) management fees charged to Limited Partners on committed capital across successive fund vehicles, and (2) carried interest on successful portfolio company exits. The Platinum Program itself is not a revenue stream but a pipeline-generation tool — a competitive award (not a priced service) that produced 24 awards and $11.35 million in deployed pre-seed capital across 22 cities by 2026. The firm's competitive differentiation rests on its co-founding stake in LabCentral (with Peter Parker and Johannes Fruehauf) and BioLabs/MBC BioLabs (operated by Doug Crawford), which collectively anchor a network of 31 incubators across the U.S., Canada, Europe, and Asia; companies started in this network routinely account for over 20% of all Seed and Series A venture capital invested in U.S. life sciences. Office footprint includes Cambridge, San Francisco, and a new Copenhagen office at the BioInnovation Institute established in April 2025.

The team comprises approximately 20 members across investment, operations, finance, and compliance, including three Managing General Partners (Douglas Crawford, Peter Parker, Steve Tregay) plus experienced operator-investors such as former Pfizer SVP Michael Taylor, FORMA Therapeutics founder Steve Tregay, Merrimack co-founder Ulrik Nielsen, and LabCentral/BioLabs founder Johannes Fruehauf. Strategic corporate sponsors anchor the Platinum Program — Eli Lilly and Ono Venture Investment as founding sponsors since 2022, with AbbVie joining in 2026 alongside service sponsors Alloy Therapeutics, HitGen, CCRM, Goodwin, Norton Rose Fulbright, and van den Boom. The portfolio includes 60+ companies since inception with notable liquidity events including IPOs (Alector, Caribou Biosciences, Zymergen) and strategic acquisitions (SiteOne/Lilly $1.0B in 2025; Dren-0201/Sanofi $600M+; Pionyr/Gilead; Vedere/Novartis; Principia/Sanofi).

Name

Mission BioCapital

Legal name

Mission BioCapital LP

Website

https://missionbiocapital.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Mission BioCapital is a Cambridge-based life science venture capital firm founded in 2009 that invests in early-stage biotech and therapeutics companies through successive funds and the Platinum Program accelerator, combining pre-seed capital, affiliated incubator lab space, and partner-provided drug discovery and legal services.

Ownership category

akta.pro rank

Product category

Life Sciences Venture Capital

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Corporate Accelerators & Startup Programs (FSANAHAD)

akta.pro secondary industry

Early-Stage Venture Capital (Series A/B) (FSANAAAB)

Keywords

• Venture capital
• Life sciences investing
• Pre-seed funding
• Biotech accelerator
• Incubator network

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Fund Management Fees: Management fees charged to Limited Partners (LPs) on committed capital, structured as recurring fees over the fund lifecycle. Mission BioCapital V LP closed at $275 million in November 2021 (more than double the prior fund); Fund VI closed at $143.75 million in 2025. The firm also raised Fund V as more than double the size of its prior fund.
2. Carried Interest and Fund Returns: Share of profits from successful portfolio company exits, including IPOs (Alector, Caribou Biosciences, Zymergen, Atreca), strategic acquisitions (SiteOne Therapeutics acquired by Eli Lilly for up to $1.0 billion in 2025; DR-0201 asset from Dren Bio acquired by Sanofi for $600 million upfront plus up to $1.3 billion in milestones; Tidal Therapeutics, Totient, and Pandion all acquired by Sanofi in 2021; Vedere acquired by Novartis in 2020; Pionyr acquired by Gilead Sciences in 2020; iPierian acquired by Bristol-Myers Squibb in 2014; Principia Biopharma acquired by Sanofi in 2020; Cell Design Labs acquired by Gilead/Kite in 2017; Zephyrus Biosciences acquired by Bio-Techne in 2016; True North Therapeutics acquired by Bioverativ in 2016; Redwood Bioscience acquired by Catalent in 2014).

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

Mission BioCapital is a life science venture capital firm that provides early-stage capital to therapeutics, diagnostics, medtech, and lab tools startups through successive fund vehicles (currently Fund VI at $143.75 million closed November 2025, following Fund V at $275 million in 2021). The firm operates a flagship annual Platinum Program that awards up to $500,000 in pre-seed SAFE capital per winner, plus guaranteed lab bench space in 22 affiliated incubator cities, drug discovery services from Alloy Therapeutics/HitGen/CCRM, legal/accounting services from Goodwin/Norton Rose Fulbright/van den Boom, and structured mentorship from the GP team and corporate sponsors (Eli Lilly, Ono, AbbVie).

Product overview

Mission BioCapital operates as a unified venture capital platform consisting of three tightly integrated components: (1) the core Investment Platform delivering early-stage capital across multiple funds (currently Fund VI closed at $143.75M in November 2025, following Fund V at $275M in 2021); (2) the Platinum Program, the firm's flagship annual accelerator established in 2022 that provides up to $500,000 pre-seed SAFE investment, guaranteed lab bench space in affiliated incubators across 22 cities, drug discovery services, legal/accounting services, and mentorship; and (3) the Shared Labs offering operated through the affiliated MBC BioLabs, LabCentral, and BioLabs incubator network. The Platinum Program itself is a modular offering with named service components integrated through partners (Alloy Therapeutics for antibody discovery, HitGen for DEL screening, CCRM for cell and gene therapy consulting, Goodwin and Norton Rose Fulbright for legal services, Van den Boom & Associates for accounting). The firm's office footprint spans Cambridge, MA and San Francisco, CA in the U.S. with a European office established at the BioInnovation Institute in Copenhagen, Denmark in April 2025. Mission BioCapital is disease- and modality-agnostic, with a strong preference for novel therapeutics and opportunistic investments in medtech and diagnostics.

Differentiator

Problem solved

Functional benefit

Brands

• Mission BioCapital Platinum Program: The firm's signature early-stage launch program offering pre-seed SAFE funding (up to $500K), lab bench space in affiliated incubators, drug discovery services from Alloy Therapeutics, HitGen, and CCRM, plus legal, accounting, and mentorship support. Platinum Ticket investments are made via Mission BioCapital Platinum Program Holding LLC.

Products and services

• Platinum Program Annual competitive launchpad program for early-stage life science entrepreneurs providing pre-seed SAFE capital, guaranteed lab bench space in 22 affiliated incubator cities globally, drug discovery services from Alloy Therapeutics/HitGen/CCRM, legal services from Goodwin/Norton Rose Fulbright, accounting services from Van den Boom & Associates, and structured scientific and business mentorship from Mission BioCapital partners and corporate sponsors. Awarded competitively through application at platinumprogram.slideroom.com, with up to 8 winners annually.
• Mission BioCapital Venture Fund Platform Sequential early-stage life sciences venture capital funds that provide seed and Series A equity financing to portfolio companies, including Therapeutics companies (primary focus), diagnostics, medical devices, lab tools, and drug delivery startups. The firm manages capital from Limited Partners and earns management fees plus carried interest on exits. Mission BioCapital also co-creates companies alongside academic researchers and entrepreneurs (e.g., ARase Therapeutics, Arclight Therapeutics, Jupiter Bioventures, Telo Therapeutics).
• Shared Labs (MBC BioLabs Partnership) Co-working laboratory infrastructure offering enabling biotech companies with little more than an idea to launch and operate. Mission BioCapital operates five Bay Area co-working labs through its affiliated organization MBC BioLabs; combined network with LabCentral (225,000 sq ft in Kendall Square, co-founded by Peter Parker and Johannes Fruehauf) and BioLabs serves over 385 startups globally. Platinum Program winners are guaranteed lab bench space within this network.

Quantifiable outcome

• $11.35M invested through Platinum Program; 24 awards issued across 22 cities
• +3 more outcomes

Named customers21 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration13 records

Feature3 records

Partnerships

13 partnerships are on record, tiered flagship founding sponsor (2026), core preferred service sponsor, regional sponsor, flagship european incubator partner, flagship founding sponsor and flagship incubator partner (co-founded).

• AbbVieflagship founding sponsor (2026)Strategic or Co-development Partner · 1 April 2026New Founding Sponsor of the 2026 Platinum Program. AbbVie joins the panel reviewing finalist pitches and contributes strategic scientific and business mentorship to winners.
• CCRMcore preferred service sponsorStrategic or Co-development Partner · 1 April 2026Newest Preferred Service Sponsor of the 2026 Platinum Program. CCRM provides at least 3 hours of consulting support to Platinum winners in the cell and gene space, drawing from across the CCRM family of companies (CCRM, OmniaBio, LineaBio, CATTI, CCRM Enterprises).
• Norton Rose Fulbrightcore preferred service sponsorImplementation/ SI/ Consulting Partner · 1 April 2026New Preferred Service Sponsor of the 2026 Platinum Program. Provides 3 partner hours of advisory services, free incorporation and filing of associated legal documents, IP strategy discussion, CARTA support, cap table advice, and up to $10K fee deferral plus 10% discount on general corporate fees.
• Toronto Innovation Acceleration Partners (TIAP)regional sponsorStrategic or Co-development Partner · 1 April 2026Regional Sponsor of the 2026 Platinum Program. Two Platinum Tickets are reserved for companies planning to incubate in Toronto. Mission BioCapital held Toronto Office Hours at BioLabs University of Toronto on April 28, 2026 to support the program.
• HitGencore preferred service sponsorStrategic or Co-development Partner · 1 April 2025Newest Preferred Service Sponsor of the 2025 and 2026 Platinum Programs. HitGen provides DEL Screening and other drug discovery research services to Platinum Program winners. Jin Li (Chairman and CEO) led the partnership announcement.
• BioInnovation Institute (BII)flagship european incubator partnerStrategic or Co-development Partner · 1 April 2025European incubator and office partner. Mission BioCapital established its first European office within BII in Copenhagen, Denmark, in April 2025. Robert Blazej (Partner) relocated to Copenhagen to launch the office. Platinum Program winners are eligible for lab space at BII.
• Goodwin Procter LLPcore preferred service sponsorImplementation/ SI/ Consulting Partner · 1 October 2024Preferred Service Sponsor providing legal services to Platinum Program winners: minimum 3 hours advisory services, free incorporation & filing of associated legal documents, day-to-day legal advice, support for SAFEs and convertible notes, contract negotiation, deferred fees, 10% discount, and up to 25 free first-year billable hours.
• van den Boom & Associatescore preferred service sponsorImplementation/ SI/ Consulting Partner · 1 October 2024Preferred Service Sponsor providing accounting and G&A services to Platinum Program winners: contracts management, accounts payable, payroll, financial reporting, investor reporting, financial modeling/cash runway, and diligence support.
• Alloy Therapeuticscore preferred service sponsorStrategic or Co-development Partner · 1 May 2024Preferred Service Sponsor providing drug discovery services to Platinum Program winners. Alloy offers up to $1M total in service for equity across all Platinum Ticket winners, including fully human monoclonal and bispecific antibody discovery, ML-driven antibody optimization and humanization, high-throughput antibody production and screening.
• Eli Lilly and Companyflagship founding sponsorStrategic or Co-development Partner · 1 June 2022Founding Sponsor of the Mission BioCapital Platinum Program since 2022. Lilly Catalyze360 contributes strategic scientific and business development mentorship to Platinum Program winners and co-funds seed capital awards. Co-sponsored the 2023, 2024, and 2025 Platinum Programs. In 2025, Lilly also acquired Mission BioCapital portfolio company SiteOne Therapeutics for up to $1.0 billion.
• Ono Venture Investment (OVI)flagship founding sponsorStrategic or Co-development Partner · 1 June 2022Founding Sponsor of the Platinum Program since 2022. OVI contributes strategic scientific and business development mentorship and co-funds pre-seed capital awards. Shunichiro Matsumoto (EVP of OVI) has been an active spokesperson for the partnership.
• LabCentralflagship incubator partner (co-founded)Strategic or Co-development Partner · 1 January 2013Co-founded by Mission BioCapital's Peter Parker and Johannes Fruehauf. Operating a total of 225,000 square-feet in Kendall Square, Cambridge, offering fully permitted laboratory and office space for as many as 100 startups comprising approximately 1,000 scientists and entrepreneurs. Steve Tregay (MBC Managing GP) serves as Chairman of the Board.
• BioLabsflagship incubator partner (co-founded)Strategic or Co-development Partner · 1 January 2010

Scale indicators11 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Lux Capital: Tech-and-life-sciences-focused venture firm investing at the intersection of biology, engineering, and computation. Comparable to Mission BioCapital in early-stage therapeutics and biotech platform investing, particularly AI-enabled drug discovery.
• Atlas Venture: Cambridge-based early-stage biotech venture firm that builds and funds life sciences startups, including through company creation and incubator partnerships. Directly comparable to Mission BioCapital in stage focus, geographic base, and emphasis on therapeutics.
• 5AM Ventures: Early-stage life sciences venture firm investing in founders across therapeutics and platform technologies. Directly comparable to Mission BioCapital in stage and sector focus, with similar fund-size profile.
• Third Rock Ventures: Boston-based biotech VC specializing in company creation and launch of therapeutics startups, often co-founding companies alongside entrepreneurs. Highly comparable to Mission BioCapital's Platinum Program-style model of operational involvement and pre-seed funding.
• ARCH Venture Partners: Long-tenured early-stage biotech VC investing across therapeutics, tools, and platform technologies from pre-seed through Series A. Comparable to Mission BioCapital in early-stage orientation and therapeutic focus, though at materially larger fund sizes.
• RA Capital Management: Healthcare-focused investment firm with dedicated biotech venture and public-market crossover capabilities, frequently leading or co-leading Series A rounds. Comparable to Mission BioCapital in early-stage therapeutics investing and founder support model.

Emerging players

• DCVC Bio: Early-stage venture firm investing in deep-tech and computational biology/biotech platforms. Comparable to Mission BioCapital in pre-seed-to-Series A biotech investing and emphasis on platform technologies, though at a smaller scale.

Broad incumbents

• Andreessen Horowitz (a16z Bio): Large multi-stage venture firm with a dedicated bio/health fund investing across therapeutics, digital health, and biotech infrastructure. Comparable to Mission BioCapital in biotech investing focus but with materially larger fund sizes and broader stage range.
• New Enterprise Associates (NEA): Large multi-stage venture firm with a dedicated healthcare practice investing across therapeutics, diagnostics, and medtech. Comparable to Mission BioCapital in life sciences focus, though NEA operates across stages and sectors with much larger fund vehicles.
• Flagship Pioneering: Cambridge-based biotech creation engine that originates and launches multiple therapeutic platform companies (e.g., Moderna). Comparable to Mission BioCapital in company-creation philosophy and Cambridge base, but operates at a far larger scale and platform breadth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/MissionBioCap
• LinkedInlinkedin.com/company/missionbiocapital

Revenue estimate

Valuation estimate

Number of profiles

Profiles20 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments90 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mission BioCapital